STOCK TITAN

Aadi Bioscience, Inc. - AADI STOCK NEWS

Welcome to our dedicated page for Aadi Bioscience news (Ticker: AADI), a resource for investors and traders seeking the latest updates and insights on Aadi Bioscience stock.

Aadi Bioscience, Inc. (NASDAQ: AADI) is a commercial-stage precision oncology company focused on the development and commercialization of therapies for cancers with alterations in the mTOR pathway. The company's lead asset, FYARRO® (sirolimus albumin-bound nanoparticles for injectable suspension), is an mTOR inhibitor targeting cancers driven by genetic alterations in mTOR pathway genes. Aadi is committed to bringing transformational therapies to cancer patients with mTOR pathway driver alterations such as those in the TSC1 or TSC2 genes.

Aadi Bioscience has received FDA approval for FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO® is designed to improve delivery, stability, solubility, and targeting compared to traditional mTOR inhibitors and is being evaluated in various clinical trials. The company's innovative approach combines nanoparticle albumin-bound (nab) technology with the potent mTOR inhibitor, sirolimus.

The company's clinical pipeline includes the Phase 2 PRECISION1 trial, a tumor-agnostic registration-intended study exploring nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations. The trial is expected to complete enrollment by the end of 2024, with interim analysis anticipated in Q3 2024.

In addition to PRECISION1, Aadi is conducting two other Phase 2 trials: one in advanced or recurrent endometrioid-type endometrial cancer (EEC) in combination with letrozole, and another in neuroendocrine tumors (NETs). Endometrial cancer is a common type of gynecologic cancer, and nab-sirolimus has shown promise in combination therapies for these difficult-to-treat cancers.

Financially, Aadi's Q1 2024 revenue from FYARRO® sales reached $5.4 million, reflecting a strong market presence as the preferred treatment for malignant PEComa. The company's robust financial position, with $88.3 million in cash and short-term investments as of March 2024, is expected to fund operations into Q4 2025.

Headquartered in Los Angeles, Aadi Bioscience is led by a team of industry veterans with extensive experience in developing and commercializing blockbuster oncology products. The company's mission is to unlock the full potential of mTOR inhibition and bring hope to patients with genetically-defined cancers.

Rhea-AI Summary
Aadi Bioscience, Inc. announces positive results from the AMPECT trial, showing efficacy and safety of nab-sirolimus in treating advanced malignant PEComa tumors of gynecologic origin. The study highlights the potential of nab-sirolimus for mTOR-driven gynecologic cancers, with consistent response rates and manageable safety profiles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Aadi Bioscience, Inc. (AADI) reports FYARRO sales of $6.3 million for Q4 2023 and $24.4 million for FY 2023, with year-over-year growth of 21% and 60%, respectively. The company's registration-directed PRECISION1 trial for nab-sirolimus in solid tumors is on track for completion by May, with an interim analysis planned for Q3 2024. Phase 2 trials in Endometrial Cancer and Neuroendocrine Tumors are actively enrolling patients, showing promising progress in mTOR-driven cancer targets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.34%
Tags
-
Rhea-AI Summary
Aadi Bioscience, Inc. (NASDAQ: AADI) will host a conference call and webcast on March 13, 2024, to report fourth quarter and full-year 2023 financial results and provide corporate updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.32%
Tags
conferences earnings
Rhea-AI Summary
Aadi Bioscience, Inc. (AADI) announces poster presentations at the 2024 AACR focusing on precision therapies for mTOR-driven cancers. Details include evaluation of nab-sirolimus in breast cancer and correlation in lung cancer xenografts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.32%
Tags
conferences
-
Rhea-AI Summary
Aadi Bioscience, Inc. (NASDAQ: AADI) announces positive long-term efficacy and safety results from the Phase 2 AMPECT trial for nab-sirolimus in malignant PEComa patients, with a 40-month median duration of response and a >53-month median survival. The trial demonstrated a 38.7% overall response rate, including complete responses, and highlighted the potential of nab-sirolimus as an effective treatment for patients with mTOR-driven cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.82%
Tags
none
-
Rhea-AI Summary
Aadi Bioscience, Inc. (AADI) to present at the TD Cowen 44th Annual Healthcare Conference in March 2024. Dave Lennon, President and CEO, to provide a company overview on precision therapies for patients with mTOR pathway alterations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
conferences
Rhea-AI Summary
Aadi Bioscience, Inc. (NASDAQ: AADI) presented poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, highlighting the analysis of inactivating alterations in TSC1 and TSC2 in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database. Key findings include the prevalence of TSC1 and/or TSC2 inactivating alterations in patients with bladder, kidney, and prostate cancer, as well as the enrollment of patients in the PRECISION 1 study for solid tumors harboring these alterations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.59%
Tags
none
-
Rhea-AI Summary
Aadi Bioscience, Inc. (AADI) presented real-world analysis at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, highlighting unmet medical need in GI cancer patients with TSC1/2 alterations. The analysis revealed that 1.4% of patients with GI cancers harbored at least one known or likely inactivating alteration in TSC1 or TSC2. The study also found that TSC1 and/or TSC2 inactivating alterations were present in 6.8% of liver cancers, 1.6% of colorectal cancers, and 0.5% of pancreatic cancers. The company is currently enrolling patients in the PRECISION 1 study (NCT05103358) for solid tumors harboring TSC1 and/or TSC2 inactivating alterations. Aadi is also presenting Trials-in-Progress (TiP) posters from its PRECISION 1 and NET clinical studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.07%
Tags
none
-
Rhea-AI Summary
Aadi Bioscience, Inc. (NASDAQ: AADI) reports promising interim results from the PRECISION1 trial evaluating nab-sirolimus in patients with TSC1 or TSC2 inactivating alterations, demonstrating sustained tumor reductions in advanced cancer patients. The trial is expected to be completed by the end of 2024, with final data readout in early 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-56.42%
Tags
none
Rhea-AI Summary
AADI - Aadi Bioscience, Inc. announces strong third-quarter financial results, including a 40% increase in FYARRO sales to $6.0 million. The company also highlights the progress of the PRECISION1 tumor-agnostic trial and the initiation of new Phase 2 studies for endometrial cancer and neuroendocrine tumors. Real-world NGS analysis reinforces the unmet need in TSC1 and TSC2 mutated cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.53%
Tags

FAQ

What is the current stock price of Aadi Bioscience (AADI)?

The current stock price of Aadi Bioscience (AADI) is $2.22 as of November 20, 2024.

What is the market cap of Aadi Bioscience (AADI)?

The market cap of Aadi Bioscience (AADI) is approximately 55.7M.

What is Aadi Bioscience, Inc.?

Aadi Bioscience, Inc. is a commercial-stage precision oncology company focused on the development and commercialization of therapies for cancers with alterations in the mTOR pathway.

What is FYARRO®?

FYARRO® (sirolimus albumin-bound nanoparticles for injectable suspension) is an mTOR inhibitor developed by Aadi Bioscience for treating cancers driven by genetic alterations in mTOR pathway genes.

What are the key clinical trials of Aadi Bioscience?

Aadi Bioscience's key clinical trials include the Phase 2 PRECISION1 trial for solid tumors with TSC1 or TSC2 inactivating alterations, a Phase 2 trial in advanced or recurrent endometrioid-type endometrial cancer (EEC) in combination with letrozole, and a Phase 2 trial in neuroendocrine tumors (NETs).

What financial results did Aadi Bioscience achieve in Q1 2024?

In Q1 2024, Aadi Bioscience achieved $5.4 million in revenue from FYARRO® sales. The company had $88.3 million in cash and short-term investments as of March 2024.

What is the significance of the mTOR pathway in cancer treatment?

The mTOR pathway is a key regulator of cell growth and cancer progression. Alterations in this pathway can lead to various cancers. Aadi Bioscience focuses on developing therapies targeting these alterations to treat genetically-defined cancers.

Where is Aadi Bioscience headquartered?

Aadi Bioscience is headquartered in Los Angeles, California.

Who leads Aadi Bioscience?

Aadi Bioscience is led by a team of industry veterans with extensive experience in developing and commercializing blockbuster oncology products.

What are the upcoming milestones for Aadi Bioscience?

Upcoming milestones for Aadi Bioscience include the two-thirds interim analysis of the PRECISION1 trial in Q3 2024, full enrollment in the trial by the end of 2024, and ongoing enrollment in Phase 2 trials for EEC and NETs.

What are the potential benefits of nab-sirolimus?

Nab-sirolimus combines nanoparticle albumin-bound technology with sirolimus to improve drug delivery, stability, solubility, and targeting, potentially overcoming limitations of traditional mTOR inhibitors.

What is the mission of Aadi Bioscience?

Aadi Bioscience's mission is to unlock the full potential of mTOR inhibition and bring transformational therapies to cancer patients with genetically-defined cancers.

Aadi Bioscience, Inc.

Nasdaq:AADI

AADI Rankings

AADI Stock Data

55.71M
22.17M
9.96%
49.17%
1.14%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PACIFIC PALISADES